In recent years, advances in molecular biology have contributed to the understanding of pancreatic cancer. Pancreatic cancer is ranked 4th in terms of cancer-related mortality and the prognosis is very poor because there is a lack of sensitive and effective techniques to diagnose and treat patients with the disease. Therefore, the primary tumor will have already reached its advanced stages and metastasized before being diagnosed. Five-year relative survival for pancreatic cancer remains at 6%. Median survival is 3 to 5 months if the cancer has metastasized and 6 to 10 months if the cancer is localized. This contrasts with the five-year survival in 1998 of U.S. patients diagnosed with breast cancer (86%) and prostate cancer (97%). It is therefore necessary for scientists to develop new techniques to diagnose and treat this disease. Better knowledge of how to treat pancreatic cancer relies largely on a better understanding of molecular biology and the development of molecular targeted therapies. Pancreatic cancer can be classified as adenocarcinoma or pancreatic cancer....